GE Healthcare Life Sciences completes transition into Cytiva
Apr 1, 2020 · In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation decided to spend $21.4bn (€19.5bn) to acquire GE Healthcare Life Sciences.. Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva.
Biopharmaceutical Manufacturing, Upstream, Downstream …
Nov 20, 2024 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
SGS acquires live biotherapeutics focused CDMO
Dec 14, 2021 · The deal is set to provide Quay, which was established in 2002, with the investment to further grow its extensive range of services and capabilities in the support of clients through the various stages of pharmaceutical clinical development, from pre-clinical to formulation, dosage form design and optimization, as well as clinical trial manufacture and supply.
Trends - biopharma-reporter.com
Nov 5, 2024 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
FDA greenlights first CAR-T therapy for multiple sclerosis trials
Aug 22, 2024 · The California-based company announced this week that the FDA had cleared an investigational new drug application (IND) for its drug candidate IMPT-514, a CD19/CD20 bispecific CAR-T cell therapy in development for patients with multiple sclerosis (MS).
About us - biopharma-reporter.com
About Biopharma Reporter. Biopharma Reporter is an essential resource for the biopharma industry, covering large molecules (biologics). We focus on the key trends shaping this dynamic sector, including contract research organizations, patient-centric innovations, AI-driven data management, and the rapidly evolving landscape of cell and gene therapies.
AstraZeneca starts new chapter as Alexion acquisition closes
Jul 21, 2021 · Marc Dunoyer, incoming CEO, Alexion and Chief Financial Officer, AstraZeneca, said: “We look forward to also applying Alexion’s complement-biology platform across areas of AstraZeneca’s broader early stage pipeline and, significantly, to the extraordinary opportunity to extend existing and future rare disease medicines to patients in many countries where AstraZeneca already has a strong ...
New wave of potential therapies to bring ‘paradigm shift’ in COPD …
Mar 25, 2024 · The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.
Cytiva and Pall Life Sciences complete integration: ‘Uniting gives …
May 2, 2023 · Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells us how the company will focus its efforts moving forward to support long-term growth of the biotech industry.
Continuous bioprocessing set to revolutionize cGMP …
Oct 31, 2022 · J.POD® facility. Innovative approaches can address current industry challenges. The trend towards precision medicines has resulted in many established biotech and pharma companies expanding their therapeutic pipelines instead of relying on the development of a few blockbuster products to generate revenue and sustain growth.